Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
复制标题

DOI:
10.1016/j.chembiol.2015.05.009
复制
发表时间:
2015-06-18
影响因子:
--
通讯作者:
Crews CM
Crews CM
中科院分区:
生物1区
文献类型:
--
作者:
Lu J;Qian Y;Altieri M;Dong H;Wang J;Raina K;Hines J;Winkler JD;Crew AP;Coleman K;Crews CM

文献摘要

参考文献

被引文献

相似文献

BRD4是溴域和外域(BET)家族成员,在多种病理环境,特别是癌症中是一个有吸引力的靶点。虽然BRD4抑制剂在MYC驱动的恶性肿瘤(如伯基特淋巴瘤(BL))中显示出一些前景,但我们发现BRD4抑制剂会导致BRD4蛋白的强烈积累,这可能解释了它们对MYC表达的有限抑制、适度的抗增殖活性和缺乏凋亡诱导。为了解决这些限制,我们设计了ARV-825,这是一种异双功能PROTAC(蛋白水解靶向嵌合体),可将BRD4招募到E3泛素连接酶小脑,从而在所有测试的BL细胞系中快速,有效和长时间地降解BRD4。因此,ARV-825比小分子BRD4抑制剂更有效地抑制c-MYC水平和下游信号传导,从而更有效地抑制BL中的细胞增殖和诱导凋亡。我们的研究结果有力地证明,基于小脑的PROTACs比传统的小分子抑制剂提供了更好、更有效的靶向BRD4的策略。
BRD4, a bromodomain and extraterminal domain (BET) family member, is an attractive target in multiple pathological settings, particularly cancer. While BRD4 inhibitors have shown some promise in MYC-driven malignancies such as Burkitt’s Lymphoma (BL), we show that BRD4 inhibitors lead to robust BRD4 protein accumulation, which may account for their limited suppression of MYC expression, modest anti-proliferative activity and lack of apoptotic induction. To address these limitations, we designed ARV-825, a heterobifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon leading to fast, efficient, and prolonged degradation of BRD4 in all BL cell lines tested. Consequently, ARV-825 more effectively suppresses c-MYC levels and downstream signaling than small molecule BRD4 inhibitors resulting in more effective cell proliferation inhibition and apoptosis induction in BL. Our findings provide strong evidence that cereblon-based PROTACs provide a better and more efficient strategy in targeting BRD4 than traditional small molecule inhibitors.
选择性抑制BET溴结构域。
DOI: 10.1038/nature09504
发表时间: 2010-12-23
期刊: Nature
影响因子: 64.8
作者:
通讯作者: --
DOI: 10.1002/anie.201307761
发表时间: 2014-02-24
影响因子: 16.6
作者:
Buckley, Dennis L.;Crews, Craig M.
通讯作者: Crews, Craig M.
DOI: 10.18632/oncotarget.1873
发表时间: 2014-05-30
期刊: Oncotarget
影响因子: --
作者:
Loosveld M;Castellano R;Gon S;Goubard A;Crouzet T;Pouyet L;Prebet T;Vey N;Nadel B;Collette Y;Payet-Bornet D
通讯作者: Payet-Bornet D
DOI: 10.1016/j.celrep.2014.08.025
发表时间: 2014-09-25
期刊: Cell reports
影响因子: 8.8
作者:
Bolden JE;Tasdemir N;Dow LE;van Es JH;Wilkinson JE;Zhao Z;Clevers H;Lowe SW
通讯作者: Lowe SW
DOI: 10.1038/leu.2012.119
发表时间: 2012-11
期刊: LEUKEMIA
影响因子: 11.4
作者:
Lopez-Girona, A.;Mendy, D.;Ito, T.;Miller, K.;Gandhi, A. K.;Kang, J.;Karasawa, S.;Carmel, G.;Jackson, P.;Abbasian, M.;Mahmoudi, A.;Cathers, B.;Rychak, E.;Gaidarova, S.;Chen, R.;Schafer, P. H.;Handa, H.;Daniel, T. O.;Evans, J. F.;Chopra, R.
通讯作者: Chopra, R.